by SEQENS | Oct 6, 2022 | Articles
Seqens, an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 industrial sites, 10 R&D centers, and 3,200 employees located on three continents, appointed Bob Huang as Managing Director of Seqens Innovation and Generic...
by SEQENS | Dec 17, 2021 | Press Releases, SEQENS
SEQENS is pleased to announce that, on December 16, 2021, funds advised by SK Capital have become the majority shareholder of the group. Two new long-term institutional investors, Bpifrance and Nov Santé are taking part in the transaction alongside SK Capital,...
by SEQENS | Oct 26, 2021 | API Manufacturing, Blog, Quality Systems, Standard Operating Procedures
From quality issues with Johnson & Johnsons’ infant pain reliever to contaminated high blood pressure medication, we all know too well the problems that can occur when mistakes happen in API manufacturing. The role of quality is paramount, since the...
by SEQENS | Oct 19, 2021 | Blog, cGMP, Technology Transfer
For a variety of reasons, pharma firms may find it necessary to transfer a development or manufacturing project from one site or firm to another, in order to address a new stage, changing requirements or scale-up. This is usually not a one-time thing, but can occur...
by SEQENS | Oct 12, 2021 | Blog, EMA, Fast Track, Quality Systems, risk management
There was a time when terms such as Emergency Use Authorization and fast track drugs were not a part of the ordinary vernacular, but then along came COVID-19. As of March 31, 2021, ten COVID-19 treatments were authorized by the FDA for emergency use and many more are...
